logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Jnana Therapeutics announced it raised $60 Million in an initial filing from an offering of $60 Million

Jnana Therapeutics announced it raised $60 Million in an initial filing from an offering of $60 Million

11/16/22, 9:44 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgboston
Money raised
$60 million
Industry
biotechnology

Company Info

Company
Jnana Therapeutics Inc.
Location
6 tide street
boston, massachusetts, united states
Additional Info
Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet need. Jnana is focused on developing first- and best-in-class therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases and cancer. Jnana’s wholly owned lead program is a potential first-in-class oral approach, targeting an allosteric site on the phenylalanine transporter SLC6A19, for the treatment of phenylketonuria (PKU), a rare genetic metabolic disease. Located in Boston, Jnana brings together scientific leaders in small molecule drug discovery and development, a highly experienced management team and the backing of leading life science investors Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures and AbbVie Ventures.

Company news

Thu, 01 Aug 2024 07:00:00 GMT

Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. - GlobeNewswire

Wed, 01 Mar 2023 08:00:00 GMT

Jnana Therapeutics to Participate in Upcoming Investor Conferences - Business Wire

Wed, 04 Sep 2024 07:00:00 GMT

Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025 - Yahoo Finance

Tue, 15 Nov 2022 08:00:00 GMT

Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform - PR Newswire

Tue, 30 Jan 2024 08:00:00 GMT

Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU - Yahoo Finance

Wed, 18 Aug 2021 07:00:00 GMT

Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform - Business Wire

Tue, 15 Nov 2022 08:00:00 GMT

Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases - PR Newswire

Tue, 21 Jul 2020 07:00:00 GMT

Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism to Treat Immune-Mediated and Neurological Diseases - Business Wire

Tue, 02 Oct 2018 07:00:00 GMT

FierceBiotech names Jnana Therapeutics as one of its “Fierce 15” Biotech Companies of 2018 - Business Wire

G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.

Related people

GH

JH

Sign up to get related executive contact information